Yamanaka T, Abo W, Chiba S, Nakao T, Masuho Y, Tomibe K, Noguchi T
Vox Sang. 1979;37(1):14-20. doi: 10.1111/j.1423-0410.1979.tb02263.x.
7 patients with primary humoral immunodeficiency were given an S-sulfonated IgG preparation, 100 mg/kg i.v. at intervals of 3--4 weeks, for treatment of, or prophylaxis against, infection. The clinical effects and metabolism of S-sulfonated IgG were studied. No side reactions attributable to S-sulfonated IgG occurred in any of the patients. The S-sulfonated IgG was completely transformed into intact IgG within 24 h after administration, and had a mean half-life of 21 days, comparable to that of intact IgG. Complete restoration of IgG Fc fragment activity occurred within 24 h following injection, as assessed by reversed passive cutaneous anaphylaxis.
7例原发性体液免疫缺陷患者接受了S-磺化IgG制剂治疗，静脉注射剂量为100mg/kg，每3 - 4周一次，用于治疗或预防感染。研究了S-磺化IgG的临床效果和代谢情况。所有患者均未出现归因于S-磺化IgG的不良反应。S-磺化IgG在给药后24小时内完全转化为完整的IgG，平均半衰期为21天，与完整IgG相当。通过反向被动皮肤过敏反应评估，注射后24小时内IgG Fc片段活性完全恢复。
